Visit Website →
← Back to blog

Semax vs Selank: Differences, Evidence and Australian Rules

November 3, 2026
Semax vs Selank: Differences, Evidence and Australian Rules

Semax and Selank are both synthetic heptapeptides developed in Russia, but they are studied for different things. Semax research centres on cognition and neuroprotection. Selank research centres on anxiety-related and GABAergic effects. Human evidence for both is small and mostly Russian, and neither is a general retail product in Australia. This guide compares them on structure, research focus, evidence, safety and legal status.

Peptasticlabs
peptasticlabs.com
Source Peptides With Clearer Documentation
Peptastic Labs offers independently tested research-grade peptides, with HPLC purity verification and Certificates of Analysis available on request.
Explore the peptide catalog

TL;DR

  • Structure: Semax is based on ACTH(4–10). Selank is an analogue of tuftsin.
  • Research focus: Semax is associated with neuroprotection and cognition. Selank is associated with anxiety-related and GABAergic effects.
  • Evidence: Human data is limited to small studies with methodological weaknesses. Certainty ratings for efficacy claims are very low.
  • Australia: The TGA says a "research purposes only" label does not make consumer supply lawful. Check compliance before any order.
  • Combination: We are not aware of controlled trials of the two together.

Table of Contents

Semax vs Selank at a glance

AttributeSemaxSelank
TypeSynthetic heptapeptideSynthetic heptapeptide
Origin of designBased on ACTH(4–10)Analogue of tuftsin
Main research associationNeuroprotection, cognitionAnxiety-related and GABAergic effects
Human researchTwo pilot studies in healthy people, two in stroke patientsSmall trials, some compared with benzodiazepines
Evidence certainty (efficacy claims)Very lowVery low
Reported tolerability issuesNasal irritationTaste or odor issues, rare allergic reactions
Australian statusNot in the ARTG as a retail productNot in the ARTG as a retail product

The structural description comes from a 2026 evidence review of therapeutic peptides, which also notes that these are research findings and not a basis for self-treatment.

What Semax is

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, ACTH(4–10). In the reviewed literature it is linked mainly to neuroprotection and cognitive research. Russian clinical use has focused on neurological settings such as stroke.

The human data is thin. An academic summary of Semax describes two pilot studies in healthy individuals and two studies in stroke patients, with little evidence that Semax improves cognition in healthy people. An evidence synthesis from the Centre for Evidence-informed research rates the certainty of its cognitive-performance and neuroprotection claims as very low. It bases that on two contributing trials downgraded for risk of bias and reporting limitations.

For a researcher, this means Semax is a legitimate subject of study. It does not mean the cognitive claims circulating online are established.

What Semax is

What Selank is

Selank is a synthetic heptapeptide analogue of tuftsin, an immune-related tetrapeptide. Research associates it with anxiety-related endpoints and GABAergic effects. The Russian manufacturer's official site presents it for stress and anxiety and offers a form for reporting adverse reactions. That is a regulatory-style claim from a Russian registration context, not an Australian one.

For gene-expression work, our write-up of Selank research and the 1 hour and 3 hour gene signals covers what researchers look at in early time-point studies.

Human trials are small. Some compared Selank with benzodiazepines, and the 2014 study was open-label, had no placebo group and was partly maker-funded, as noted in a science news review of the literature. Those design features limit how far the results can be generalised.

How the proposed effects differ

The simplified summary is that Semax leans toward cognition and neuroprotection, and Selank leans toward anxiety and stress endpoints. That is a fair description of where the research literature concentrates. It is not a statement of what either compound does in a person.

Three points keep the comparison honest:

  1. Different endpoints. Studies of the two measure different outcomes, so head-to-head claims are not supported by direct comparison trials.
  2. Different populations. Semax work includes stroke patients. Selank work includes people with anxiety-related conditions. Results do not transfer to healthy adults.
  3. Different regulatory histories. Russian registration is not equivalent to independently replicated Western trials. The same evidence review treats evidence quality and regulatory status as separate questions.

Evidence quality: what the grading says

An evidence institute grading Russian-registered neuropeptides rates efficacy claims as very low certainty. It says the rating reflects what it could verify, since it could not retrieve a trial report with a protocol, randomisation procedure and prespecified analysis plan. It states that this is not a judgement on the regulator.

The practical reading for a research buyer:

  • Treat published effect sizes as hypotheses.
  • Look for replication outside the original Russian groups.
  • Design in-vitro or preclinical protocols with clear controls and documented material.

Safety and tolerability questions

Reported tolerability issues are modest but not well characterised. Semax reports include nasal irritation. Selank reports include taste or odor issues and rare allergic reactions. Long-term safety has not been firmly established, according to a peptide comparison article.

Reported Semax and Selank tolerability issues

The US FDA has also flagged compounded Semax and Selank acetate as a concern. It cites possible immunogenicity risks from aggregation and peptide impurities, and notes that safety information is limited or missing. Both points are about material quality, which is why identity and purity documentation matters.

Anyone with a medical condition, or taking prescription medication, should speak with a doctor before considering any unapproved therapeutic good. Research material is not a substitute for medical care.

Can Semax and Selank be combined?

Online discussion often treats the two as complementary: one for focus, one for calm. We are not aware of controlled studies establishing that the combination is safe or effective. Without such data, the combination is an untested hypothesis. In a laboratory setting, it means any combined-compound design needs its own controls, with each peptide tested alone and together.

This is where most readers in Australia need clarity.

  • The TGA's Special Access Scheme guidance states that therapeutic goods generally must be in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully imported, supplied or exported. Goods outside the ARTG are "unapproved".
  • The same guidance describes the Special Access Scheme as a practitioner-led pathway for particular patients. It is not ARTG approval or general retail authorisation.
  • The TGA's page on performance and image enhancing drugs says most such drugs are illegal to supply to consumers without a prescription. It adds that a "research purposes only" label does not make consumer supply lawful, and that possession without a prescription may be illegal depending on the state or territory.
  • The TGA also explains that a product likely to be perceived as a therapeutic good is regulated as one, and that "not for human use" wording does not decide its legal status.
  • On imports, Australian Border Force lists medicines among goods that may be prohibited or restricted. An overseas seller offering a peptide does not show that import is lawful.

In short: Peptastic Labs materials are supplied for laboratory research by qualified researchers and institutions, not for human use, and orders should be placed on that basis. Our guides set out the detail:

What to verify before using either peptide in research

Identity and purity are the first questions, because supply of both compounds has a track record of inconsistency. A Belgian analytical study reported two suspicious preparations in 2017 and 2018 that contained Selank and Semax, sold online as powders for injection or nasal sprays. It also developed a validated LC-MS/MS method to identify the peptides correctly. The TGA's consumer-safety view is that online or research-labelled products may be counterfeit, contaminated or inaccurately labelled.

A practical checklist:

  • HPLC purity report for the specific batch, with the stated percentage and chromatogram.
  • Mass spectrometry identity confirmation, matching the expected molecular weight.
  • Batch number traceability from the vial label to the document.
  • Certificate of Analysis that names the testing laboratory and date.
  • Storage and reconstitution guidance from the supplier, so handling matches how the material was tested.
  • Customs and compliance paperwork appropriate to an Australian institution.

Perspective

Comparisons of Semax and Selank usually fail at the same point: they rank effects while ignoring the material. A result in a paper is only as useful as the identity and purity of the compound behind it.

Our approach is documentation first. Each batch is tested independently by HPLC and mass spectrometry, with traceable batch records. Certificates of Analysis are available on request. Our catalogue is verified to ≥99% purity by HPLC, so researchers can tie their results to a specific, documented batch.

For Australian researchers, we also recommend reading the TGA position before ordering. Compliance and quality are the same discipline: know what the material is, and know what the rules allow.

Tintastic

Sourcing research-grade material

Peptastic Labs supplies independently tested, research-grade peptides for laboratory research across metabolic, cognitive and neuro, tissue and repair, longevity, cosmetic science and other lines. Each is supplied with batch documentation, and Certificates of Analysis are available on request. Bulk and wholesale options are available for institutions. Browse the full peptide catalogue and check availability of the compound you need.

Peptasticlabs

For budgeting, our guide to peptide costs in Australia explains what drives vial pricing. Examples of lawful lab work are in Australian peptide research use.

FAQ

Is Semax or Selank better?

Neither is better in general, because they are studied for different endpoints. Semax research concentrates on cognition and neuroprotection, Selank research on anxiety-related effects. Both have very-low-certainty efficacy evidence, so the right choice depends on the research question and not on a ranking.

Should Semax and Selank be used together?

There are no controlled studies we know of that establish the combination as safe or effective. In a laboratory design, test each peptide alone and in combination with proper controls. Anyone considering human use should see a doctor, since both are unapproved therapeutic goods in Australia.

Neither is in the ARTG as a retail product, and the TGA says a "research purposes only" label does not make consumer supply lawful. Practitioner-led access can exist through the Special Access Scheme for particular patients. Check the TGA and your state or territory rules before importing or possessing either.

What side effects have been reported?

Semax reports include nasal irritation. Selank reports include taste or odor issues and rare allergic reactions. Long-term safety is not firmly established, and the FDA has raised immunogenicity concerns about impure or aggregated material.

What should a Certificate of Analysis show?

It should show the batch number, HPLC purity, mass spectrometry identity confirmation, the testing laboratory and the test date. A document that cannot be tied to the vial's batch number is not useful for traceability.

Sources